iosBio
iosBio is a UK-based biotechnology company developing thermostable, orally delivered vaccines. The company focuses on formulation and delivery of non-replicating viral vector vaccines in oral capsule form, enhanced antigen presentation, and AI-assisted antigen design to accelerate vaccine discovery and enable mucosal and systemic immunity. Its lead program is an oral Epstein‑Barr Virus (EBV) vaccine candidate being advanced toward clinical testing.
Industries
Nr. of Employees
small (1-50)
iosBio
Haywards Heath, West Sussex, United Kingdom, Europe
Products
Oral thermostable EBV vaccine candidate (lead program)
A first‑in‑class, orally administered, thermostable vaccine candidate targeting Epstein‑Barr Virus, reported to induce strong antibody responses in preclinical studies and being prepared for Phase 1 clinical testing.
Oral thermostable EBV vaccine candidate (lead program)
A first‑in‑class, orally administered, thermostable vaccine candidate targeting Epstein‑Barr Virus, reported to induce strong antibody responses in preclinical studies and being prepared for Phase 1 clinical testing.
Services
AI-assisted antigen design
Computational antigen screening and structural optimization to improve immunogenicity, stability and manufacturability.
Thermostable oral vaccine delivery platform
Formulation and oral capsule delivery service for thermally-stabilised viral vector vaccines designed to enable room-temperature distribution and self-administration.
Enhanced antigen display platform
Engineering of antigen presentation on host cells to increase surface density and persistence to boost immune responses.
AI-assisted antigen design
Computational antigen screening and structural optimization to improve immunogenicity, stability and manufacturability.
Thermostable oral vaccine delivery platform
Formulation and oral capsule delivery service for thermally-stabilised viral vector vaccines designed to enable room-temperature distribution and self-administration.
Enhanced antigen display platform
Engineering of antigen presentation on host cells to increase surface density and persistence to boost immune responses.
Expertise Areas
- Oral vaccine development
- Thermostable vaccine formulation
- Viral vector engineering
- Antigen design using AI
Key Technologies
- Thermostable oral capsule vaccine delivery
- Non-replicating adenoviral vector engineering
- Antigen surface display enhancement
- AI-driven antigen design (in silico optimization)